Literature DB >> 30573390

Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study.

Jennifer A Flemming1, Yvonne Dewit2, Jeffrey M Mah3, James Saperia3, Patti A Groome4, Christopher M Booth5.   

Abstract

BACKGROUND: Recent data show that the prevalence of chronic liver disease and cirrhosis is increasing in adolescents and young adults in the USA. We aimed to describe the epidemiology of cirrhosis using an age-period-cohort approach to define birth-cohort effects on the incidence of cirrhosis in Ontario, Canada.
METHODS: We did a retrospective population-based cohort study in Ontario, Canada, using linked administrative health data from the databases of ICES, formerly the Institute for Clinical Evaluative Sciences. Patients aged at least 18 years with cirrhosis were identified by use of a validated case definition (defined as at least one inpatient or outpatient visit with a diagnosis of cirrhosis or oesophageal varices without bleeding). We calculated annual standardised incidence and prevalence in the general population. We used an age-period-cohort approach to assess the independent association between birth cohort and incidence of cirrhosis in men and women.
FINDINGS: Between Jan 1, 1997, and Dec 31, 2016, 165 979 individuals with cirrhosis were identified. The age-standardised incidence increased over the study (from 70·6 per 100 000 person-years in 1997 to 89·6 per 100 000 person-years in 2016) as did the prevalence (from 0·42% in 1997 to 0·84% in 2016). Using age-period-cohort modelling and the median birth year as the reference, the incidence of cirrhosis was higher in participants born in 1980 (incidence rate ratio 1·55, 95% CI 1·50-1·59, p<0·0001); and in participants born in 1990 (2·16, 95% CI 2·06-2·27, p<0·0001) compared with a person of the same age born in 1951. The increase in incidence of cirrhosis was greater in women than in men (eg, women born in 1990: 2·60, 95% CI 2·41-2·79; men born in 1990: 1·98, 1·85-2·12).
INTERPRETATION: The incidence of cirrhosis has increased over the past two decades, and more so in younger birth cohorts and in women. Future studies to define the cause and natural history of cirrhosis in these groups are essential to develop strategies that could reverse these trends for future generations. FUNDING: Southeastern Ontario Academic Medical Association New Clinician Scientist Award; American Association for the Study of Liver Disease (AASLD) Foundation Clinical, Translational and Outcomes Research Award in Liver Disease (JAF).
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30573390     DOI: 10.1016/S2468-1253(18)30339-X

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  23 in total

Review 1.  Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.

Authors:  S Perera; D Kelly; G M O'Kane
Journal:  Curr Oncol       Date:  2020-11-01       Impact factor: 3.677

2.  Coordination of Care Is Associated With Survival and Health Care Utilization in a Population-Based Study of Patients With Cirrhosis.

Authors:  Shirley Cohen-Mekelburg; Akbar K Waljee; Brooke C Kenney; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-09       Impact factor: 11.382

3.  Noninvasive Tests for Prognosticating Outcomes in Patients With Chronic Liver Disease in Pregnancy: Ready for Prime Time?

Authors:  Tatyana Kushner; Monika Sarkar; Tram Tran
Journal:  Am J Gastroenterol       Date:  2019-02       Impact factor: 10.864

Review 4.  Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.

Authors:  Alisa Likhitsup; Neehar D Parikh
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

Review 5.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

6.  CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges.

Authors:  Nianan Luo; Wenjun Zhong; Jiangbin Li; Jianguo Lu; Rui Dong
Journal:  Mol Biol Rep       Date:  2022-08-12       Impact factor: 2.742

7.  Impact of specialized multidisciplinary care on cirrhosis outcomes and acute care utilization.

Authors:  Michelle Carbonneau; Tracy Davyduke; Stephen E Congly; Mang M Ma; Kim Newnham; Vanessa Den Heyer; Puneeta Tandon; Juan G Abraldes
Journal:  Can Liver J       Date:  2021-02-24

8.  Early hospital readmission and survival in patients with cirrhosis: A population-based study.

Authors:  Jeffrey M Mah; Yvonne Dewit; Patti Groome; Maya Djerboua; Christopher M Booth; Jennifer A Flemming
Journal:  Can Liver J       Date:  2019-08-27

9.  Attacking Alcohol-Related Liver Disease by Taxing Alcohol Sales.

Authors:  Elliot B Tapper; Neehar D Parikh; Suthat Liangpunsakul
Journal:  Alcohol Clin Exp Res       Date:  2020-12-13       Impact factor: 3.455

Review 10.  The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease.

Authors:  Andrea Gajos; Elliot B Tapper
Journal:  Clin Ther       Date:  2020-12-30       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.